Vivoryon Therapeutics N.V. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was EUR 28.16 million compared to EUR 12.66 million a year ago. Basic loss per share from continuing operations was EUR 1.28 compared to EUR 0.63 a year ago.